Table 7.
Main Ongoing Trials of Cancer Vaccines Combined with ICIs
| Trial | Cancer Type | Line of Treatment | Vaccine | Immunotherapy | Phase |
|---|---|---|---|---|---|
| NCT03380871 | Non-squamous NSCLC | 1 | NEO-PV-01 | Pembrolizumab + chemotherapy | I |
| NCT03647163 | NSCLC | ≥2 | VSV-IFNβ-NIS | Pembrolizumab | I |
| NCT04266730 | Squamous NSCLC, SCCHN | ≥1 | PANDA-VAC | Pembrolizumab | I |
| NCT03948763 | NSCLC, CRC, Pancreatic Neoplasms | ≥3 | V941 | Pembrolizumab | I |
| NCT03311334 | Solid tumors | ≥2 | DSP-7888 | Nivolumab | I/II |
| NCT02955290 | NSCLC, SCCHN | ≥2 | CIMAvax | Nivolumab | I/II |
| NCT02879760 | NSCLC | ≥3 | Ad-MAGEA3 and MG1-MAGEA3 | Pembrolizumab | I/II |
| NCT02823990 | Non-squamous NSCLC | ≥2 | TG4010 | Nivolumab | II |
| NCT03353675 | Non-squamous NSCLC | 1 | TG4010 | Nivolumab + Chemotherapy | II |
Abbreviations: CRC, colorectal cancer; SCCHN, squamous cell carcinoma of the head and neck.